159 related articles for article (PubMed ID: 29520648)
1. Time to Surgery: a Misguided Quality Metric in Early Stage Pancreatic Cancer.
Mirkin KA; Hollenbeak CS; Wong J
J Gastrointest Surg; 2018 Aug; 22(8):1365-1375. PubMed ID: 29520648
[TBL] [Abstract][Full Text] [Related]
2. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
[TBL] [Abstract][Full Text] [Related]
3. Time to Treatment: Measuring Quality Breast Cancer Care.
Polverini AC; Nelson RA; Marcinkowski E; Jones VC; Lai L; Mortimer JE; Taylor L; Vito C; Yim J; Kruper L
Ann Surg Oncol; 2016 Oct; 23(10):3392-402. PubMed ID: 27503492
[TBL] [Abstract][Full Text] [Related]
4. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.
Hue JJ; Sugumar K; Markt SC; Hardacre JM; Ammori JB; Rothermel LD; Winter JM; Ocuin LM
Surgery; 2021 Jul; 170(1):207-214. PubMed ID: 33454134
[TBL] [Abstract][Full Text] [Related]
5. Underuse of surgical resection among elderly patients with early-stage pancreatic cancer.
He W; Zhao H; Chan W; Lopez D; Shroff RT; Giordano SH
Surgery; 2015 Nov; 158(5):1226-34. PubMed ID: 26138347
[TBL] [Abstract][Full Text] [Related]
6. Evidence for treatment and survival disparities by age in pancreatic adenocarcinoma: a population-based analysis.
Amin S; Lucas AL; Frucht H
Pancreas; 2013 Mar; 42(2):249-53. PubMed ID: 22836862
[TBL] [Abstract][Full Text] [Related]
7. Influence of facility type on survival outcomes after pancreatectomy for pancreatic adenocarcinoma.
Chu QD; Zhou M; Peddi P; Medeiros KL; Zibari GB; Shokouh-Amiri H; Wu XC
HPB (Oxford); 2017 Dec; 19(12):1046-1057. PubMed ID: 28967535
[TBL] [Abstract][Full Text] [Related]
8. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.
Heller DR; Nicolson NG; Ahuja N; Khan S; Kunstman JW
JAMA Surg; 2020 Feb; 155(2):e195047. PubMed ID: 31800002
[TBL] [Abstract][Full Text] [Related]
9. Impact of different surgical procedures on survival outcomes of patients with adenocarcinoma of pancreatic neck.
Zheng Z; Tan C; Chen Y; Ping J; Wang M
PLoS One; 2019; 14(5):e0217427. PubMed ID: 31125386
[TBL] [Abstract][Full Text] [Related]
10. Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery.
Swords DS; Zhang C; Presson AP; Firpo MA; Mulvihill SJ; Scaife CL
Surgery; 2018 Apr; 163(4):753-760. PubMed ID: 29248179
[TBL] [Abstract][Full Text] [Related]
11. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.
Johnston WC; Hoen HM; Cassera MA; Newell PH; Hammill CW; Hansen PD; Wolf RF
HPB (Oxford); 2016 Jan; 18(1):21-8. PubMed ID: 26776847
[TBL] [Abstract][Full Text] [Related]
12. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
13. The Interval Between Preoperative Radiation and Surgery Is Not Associated with Overall Survival for Soft-tissue Sarcomas: An Analysis of the National Cancer Database.
Collier CD; Kim CY; Liu RW; Getty PJ
Clin Orthop Relat Res; 2021 Mar; 479(3):506-517. PubMed ID: 32401002
[TBL] [Abstract][Full Text] [Related]
14. National failure to operate on early stage pancreatic cancer.
Bilimoria KY; Bentrem DJ; Ko CY; Stewart AK; Winchester DP; Talamonti MS
Ann Surg; 2007 Aug; 246(2):173-80. PubMed ID: 17667493
[TBL] [Abstract][Full Text] [Related]
15. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
Mirkin KA; Hollenbeak CS; Wong J
Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
[TBL] [Abstract][Full Text] [Related]
16. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume.
Bilimoria KY; Bentrem DJ; Ko CY; Tomlinson JS; Stewart AK; Winchester DP; Talamonti MS
Cancer; 2007 Sep; 110(6):1227-34. PubMed ID: 17654662
[TBL] [Abstract][Full Text] [Related]
17. Association of facility type with overall survival in patients with nonsurgically managed pancreatic cancer.
McAllister J; Amin S; Lin C
Future Oncol; 2022 Mar; 18(10):1273-1284. PubMed ID: 35114803
[TBL] [Abstract][Full Text] [Related]
18. Total compared with partial pancreatectomy for pancreatic adenocarcinoma: assessment of resection margin, readmission rate, and survival from the U.S. National Cancer Database.
Passeri MJ; Baker EH; Siddiqui IA; Templin MA; Martinie JB; Vrochides D; Iannitti DA
Curr Oncol; 2019 Jun; 26(3):e346-e356. PubMed ID: 31285679
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
20. Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival.
Olecki EJ; Stahl KA; Torres MB; Peng JS; Shen C; Dixon MEB; Gusani NJ
J Surg Oncol; 2021 Jul; 124(1):79-87. PubMed ID: 33836095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
